AMCP's Cate Lockhart on why only 18% of payers regularly use real-world evidence, and what the new AMCP RWE Standards are doing to change that.
Cate Lockhart, PharmD, PhD
Advertisement
Cate Lockhart, PharmD, PhD, is chief science officer, AMCP.
Articles by Cate Lockhart, PharmD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How the US Section 301 Probe Targets Germany's Drug Pricing
2
Philip Sclafani: Will PBM Reform Actually Lower Net Drug Costs?
3
Payers Want Real-World Evidence. Why Aren't They Using It?
4
How GLP-1 Growth and Specialty Drugs Are Driving Cost Pressure
5